<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01767935</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00020528</org_study_id>
    <secondary_id>NCI-2012-02087</secondary_id>
    <secondary_id>P30CA012197</secondary_id>
    <secondary_id>CCCWFU 97212</secondary_id>
    <nct_id>NCT01767935</nct_id>
  </id_info>
  <brief_title>Cryosurgery and Radiation Therapy in Treating Patients With Painful Bone Metastases</brief_title>
  <official_title>A Pilot Study of The Tandem Treatment of Painful Osseous Metastases With Cryoablation Followed by Radiation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Endocare, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies cryosurgery and radiation therapy in treating patients with&#xD;
      painful bone metastases. Cryosurgery kills tumor cells by freezing them. Radiation therapy&#xD;
      uses high-energy x-rays and other types of radiation to kill tumor cells and shrink tumors.&#xD;
      Giving cryosurgery together with radiation therapy may kill more tumor cells&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the potential for efficacy and safety of combining percutaneous computed&#xD;
      tomography (CT)-guided cryoablation and radiotherapy for the palliation of osseous&#xD;
      metastases.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo cryosurgery. Beginning 2 weeks later, patients undergo 1, 10, or 15&#xD;
      fractions of radiation therapy 5 days per week for 1-3 weeks. Treatment continues in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 24 hours and weeks 1-2, 4,&#xD;
      12, 18, and 24.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow Accruals&#xD;
  </why_stopped>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Level at 24 Hours Before Cryosurgery, as Measured by the BPI</measure>
    <time_frame>24 hours</time_frame>
    <description>Numerical scores (0-10) from the BPI will be used to measure pain levels. Higher scores denotes worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Medication Level, Assessed by Changes in Narcotic Medication Usage</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Pain medication assessments will be used to quantify any change in narcotic medication usage using the 24-hour morphine equivalent dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events, Graded According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain After Cryosurgery, as Measured by the BPI</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Questions #4 (least pain), #5 (average pain), and #6 (right now) from the BPI (reported on 0-10 scale) will be used as the secondary outcome measures. Higher scores denotes worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Survived</measure>
    <time_frame>Up to 24 weeks post-cryosurgery</time_frame>
    <description>Count of participants that survived.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Bone Metastases</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Treatment (cryosurgery and radiation therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo cryosurgery. Beginning 2 weeks later, patients undergo 1, 10, or 15 fractions of radiation therapy 5 days per week for 1-3 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cryosurgery</intervention_name>
    <description>Undergo cryosurgery</description>
    <arm_group_label>Treatment (cryosurgery and radiation therapy)</arm_group_label>
    <other_name>cryoablation</other_name>
    <other_name>cryosurgical ablation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Undergo radiation therapy</description>
    <arm_group_label>Treatment (cryosurgery and radiation therapy)</arm_group_label>
    <other_name>irradiation</other_name>
    <other_name>radiotherapy</other_name>
    <other_name>therapy, radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (cryosurgery and radiation therapy)</arm_group_label>
    <other_name>quality of life assessment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically (histologically or cytologically) confirmed metastatic disease with a&#xD;
             new tumor involving or abutting bone that has the clinical and imaging features of&#xD;
             metastatic disease&#xD;
&#xD;
               -  If the nature of the metastatic disease has been previously documented, index&#xD;
                  tumor to be treated does not require further documentation (i.e., biopsy)&#xD;
&#xD;
          -  Current analgesic therapies have failed (worst pain of 4 or above as measured by Brief&#xD;
             Pain Inventory [BPI], despite analgesic therapy) OR the subject is experiencing&#xD;
             intolerable side effects that preclude analgesic use (resulting in pain of 4 or above,&#xD;
             as measured by BPI)&#xD;
&#xD;
          -  Pain must be from one or two painful metastatic sites in the bone (additional less&#xD;
             painful metastatic sites may be present)&#xD;
&#xD;
               -  Pain from the reported one or two metastatic sites must correlate with an&#xD;
                  identifiable tumor on CT, magnetic resonance imaging (MRI), or ultrasound (US)&#xD;
                  imaging&#xD;
&#xD;
               -  Metastatic tumors must be amenable to cryoablation with CT or MRI&#xD;
&#xD;
          -  If the index tumor is in the spine, there must be an intact cortex between the mass&#xD;
             and the spinal canal and exiting nerve roots&#xD;
&#xD;
          -  Patients must have stable use of hormonal therapy for two weeks prior to study&#xD;
             registration and two weeks prior to cryoablation procedure)&#xD;
&#xD;
          -  Stable use of pain medications (no changes within two weeks of cryoablation procedure)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2&#xD;
&#xD;
          -  Life expectancy &gt;= 2 months&#xD;
&#xD;
          -  Platelets &gt; 50,000/mm^3&#xD;
&#xD;
          -  International normalized ratio (INR) &gt;= 1.5&#xD;
&#xD;
          -  Patients may not have any debilitating medical or psychiatric illness that would&#xD;
             preclude giving informed consent or receiving optimal treatment and follow-up&#xD;
&#xD;
          -  Patients who are taking antiplatelet or anticoagulation medication (e.g., aspirin,&#xD;
             ibuprofen, low molecular weight heparin [LMWH] preparations) must be able to&#xD;
             discontinue such treatment prior to the cryoablation procedure for an appropriate&#xD;
             amount of time; at least 5 days should be allowed after discontinuation of aspirin,&#xD;
             Coumadin, clopidogrel, and dipyridamole; at least 12 hours should be allowed after&#xD;
             discontinuation of LMWH preparations&#xD;
&#xD;
          -  Patients must be clinically suitable for cryoablation therapy&#xD;
&#xD;
          -  Patients must be clinically suitable for radiation therapy&#xD;
&#xD;
          -  Patients must be able to understand and willing to sign a written informed consent&#xD;
             document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a diagnosis of leukemia, lymphoma, or myeloma&#xD;
&#xD;
          -  Patients with a tumor involving a weight-bearing long bone of the lower extremity with&#xD;
             the tumor causing &gt; 50% loss of cortical bone&#xD;
&#xD;
          -  Patients who have undergone prior ablation treatment or radiation therapy of the index&#xD;
             tumor&#xD;
&#xD;
          -  Patients who have received chemotherapy within 14 days prior to and 14 days after&#xD;
             cryoablation procedure&#xD;
&#xD;
          -  Index tumor(s) causing clinical or radiographic evidence of spinal cord or cauda&#xD;
             equine compression/effacement&#xD;
&#xD;
          -  Anticipated treatment of the index tumor that would require iceball formation within&#xD;
             1.0 cm of the spinal cord, brain, other critical nerve structure, large abdominal&#xD;
             vessel such as the aorta or inferior vena cava (IVC), bowel, or bladder&#xD;
&#xD;
          -  Any prior surgery at the proposed treatment site OR any prior surgery involving the&#xD;
             cryoablation-treated tumor&#xD;
&#xD;
          -  Index tumor involves the skull (treatment of other painful tumors in subjects with&#xD;
             skull tumors is not excluded)&#xD;
&#xD;
          -  Patients with uncontrolled coagulopathy or bleeding disorders&#xD;
&#xD;
          -  Patients who are pregnant, nursing, or who wish to become pregnant during the study&#xD;
&#xD;
          -  Patients with active, uncontrolled infection&#xD;
&#xD;
          -  Patients with serious medical illnesses, including any of the following: uncontrolled&#xD;
             congestive heart failure, uncontrolled angina, myocardial infarction, cerebrovascular&#xD;
             event within six months prior to study entry&#xD;
&#xD;
          -  Patients who are concurrently participating in any other experimental studies that&#xD;
             could affect the primary endpoint of this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Childs</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Comprehensive Cancer Center of Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>January 11, 2013</study_first_submitted>
  <study_first_submitted_qc>January 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2013</study_first_posted>
  <results_first_submitted>November 17, 2017</results_first_submitted>
  <results_first_submitted_qc>November 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 13, 2017</results_first_posted>
  <last_update_submitted>October 17, 2018</last_update_submitted>
  <last_update_submitted_qc>October 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Cryosurgery and Radiation Therapy)</title>
          <description>Patients undergo cryosurgery. Beginning 2 weeks later, patients undergo 1, 10, or 15 fractions of radiation therapy 5 days per week for 1-3 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
cryosurgery: Undergo cryosurgery&#xD;
radiation therapy: Undergo radiation therapy&#xD;
quality-of-life assessment: Ancillary studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Cryosurgery and Radiation Therapy)</title>
          <description>Patients undergo cryosurgery. Beginning 2 weeks later, patients undergo 1, 10, or 15 fractions of radiation therapy 5 days per week for 1-3 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
cryosurgery: Undergo cryosurgery&#xD;
radiation therapy: Undergo radiation therapy&#xD;
quality-of-life assessment: Ancillary studies</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Level at 24 Hours Before Cryosurgery, as Measured by the BPI</title>
        <description>Numerical scores (0-10) from the BPI will be used to measure pain levels. Higher scores denotes worse outcome.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Cryosurgery and Radiation Therapy)</title>
            <description>Patients undergo cryosurgery. Beginning 2 weeks later, patients undergo 1, 10, or 15 fractions of radiation therapy 5 days per week for 1-3 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
cryosurgery: Undergo cryosurgery&#xD;
radiation therapy: Undergo radiation therapy&#xD;
quality-of-life assessment: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Level at 24 Hours Before Cryosurgery, as Measured by the BPI</title>
          <description>Numerical scores (0-10) from the BPI will be used to measure pain levels. Higher scores denotes worse outcome.</description>
          <units>score on a scale</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Medication Level, Assessed by Changes in Narcotic Medication Usage</title>
        <description>Pain medication assessments will be used to quantify any change in narcotic medication usage using the 24-hour morphine equivalent dose.</description>
        <time_frame>Baseline to 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Cryosurgery and Radiation Therapy)</title>
            <description>Patients undergo cryosurgery. Beginning 2 weeks later, patients undergo 1, 10, or 15 fractions of radiation therapy 5 days per week for 1-3 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
cryosurgery: Undergo cryosurgery&#xD;
radiation therapy: Undergo radiation therapy&#xD;
quality-of-life assessment: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Medication Level, Assessed by Changes in Narcotic Medication Usage</title>
          <description>Pain medication assessments will be used to quantify any change in narcotic medication usage using the 24-hour morphine equivalent dose.</description>
          <units>mg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events, Graded According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0</title>
        <time_frame>Up to 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Cryosurgery and Radiation Therapy)</title>
            <description>Patients undergo cryosurgery. Beginning 2 weeks later, patients undergo 1, 10, or 15 fractions of radiation therapy 5 days per week for 1-3 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
cryosurgery: Undergo cryosurgery&#xD;
radiation therapy: Undergo radiation therapy&#xD;
quality-of-life assessment: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events, Graded According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0</title>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain After Cryosurgery, as Measured by the BPI</title>
        <description>Questions #4 (least pain), #5 (average pain), and #6 (right now) from the BPI (reported on 0-10 scale) will be used as the secondary outcome measures. Higher scores denotes worse outcome</description>
        <time_frame>Up to 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Cryosurgery and Radiation Therapy)</title>
            <description>Patients undergo cryosurgery. Beginning 2 weeks later, patients undergo 1, 10, or 15 fractions of radiation therapy 5 days per week for 1-3 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
cryosurgery: Undergo cryosurgery&#xD;
radiation therapy: Undergo radiation therapy&#xD;
quality-of-life assessment: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Pain After Cryosurgery, as Measured by the BPI</title>
          <description>Questions #4 (least pain), #5 (average pain), and #6 (right now) from the BPI (reported on 0-10 scale) will be used as the secondary outcome measures. Higher scores denotes worse outcome</description>
          <units>score on a scale</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Least pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right now</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Survived</title>
        <description>Count of participants that survived.</description>
        <time_frame>Up to 24 weeks post-cryosurgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Cryosurgery and Radiation Therapy)</title>
            <description>Patients undergo cryosurgery. Beginning 2 weeks later, patients undergo 1, 10, or 15 fractions of radiation therapy 5 days per week for 1-3 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
cryosurgery: Undergo cryosurgery&#xD;
radiation therapy: Undergo radiation therapy&#xD;
quality-of-life assessment: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Survived</title>
          <description>Count of participants that survived.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Cryosurgery and Radiation Therapy)</title>
          <description>Patients undergo cryosurgery. Beginning 2 weeks later, patients undergo 1, 10, or 15 fractions of radiation therapy 5 days per week for 1-3 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
cryosurgery: Undergo cryosurgery&#xD;
radiation therapy: Undergo radiation therapy&#xD;
quality-of-life assessment: Ancillary studies</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. David Childs</name_or_title>
      <organization>Wake Forest University Health Sciences</organization>
      <phone>336-716-2471</phone>
      <email>dchilds@wakehealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

